Semaglutide linked to 26% lower 5-year predicted dementia risk
Semaglutide, widely known for weight loss, is now linked to a 26% lower 5-year predicted dementia risk in a new study. Hacker News was quick to scrutinize the Novo Nordisk-funded research, questioning its reliance on predictive biomarkers over clinical outcomes. Commenters debated the study's validity and shared varied experiences with GLP-1 drugs, highlighting both their "magical" metabolic benefits and challenging side effects.
The Lowdown
A new study published in Alzheimer's & Dementia: Translational Research & Clinical Interventions suggests that semaglutide, a GLP-1 receptor agonist, may reduce the 5-year predicted risk of dementia by 26%. This finding, stemming from a post-hoc analysis of the SELECT trial, opens a potential new therapeutic avenue for the drug, already popular for weight management and diabetes.
- The study, funded by Novo Nordisk (manufacturer of Semaglutide, e.g., Ozempic, Wegovy), analyzed data from nearly 3,000 older adults (aged 65+) with overweight/obesity and cardiovascular disease but no diabetes.
- Instead of tracking actual dementia diagnoses, researchers used the "Dementia SomaSignal Test" (dSST), a 25-protein risk score, to estimate future dementia risk.
- Semaglutide treatment was associated with a 26.0% lower 5-year predicted event rate and an 8.8% lower 20-year predicted risk compared to placebo.
- A sensitivity analysis indicated that 72% of the observed effect on the risk score persisted after accounting for changes in BMI, suggesting that mechanisms beyond just weight loss might contribute to the proteomic signature modification.
While the study presents intriguing correlations, its reliance on a predictive biomarker, post-hoc analysis, and industry funding has prompted skepticism among critics regarding the direct clinical translation of these findings to actual dementia prevention. The potential role of GLP-1s in neurodegenerative diseases remains an active area of research.
The Gossip
Skeptical Study Scrutiny
Many commenters immediately flagged the study's funding by Novo Nordisk and its use of "predictive biomarkers" instead of actual dementia cases, arguing it's a marketing effort. They highlighted that previous dedicated trials for Alzheimer's had failed. The discussion emphasized the need for real clinical outcomes over changes in markers, especially given the history of Alzheimer's research and the commercial interests involved.
Personal Perils and Potent Promises
Users shared mixed personal experiences with GLP-1 drugs. Many reported significant benefits like 40lb weight loss, resolution of NAFLD, and reduced inflammation. However, others detailed challenging side effects including profound lack of energy, new arthritis symptoms, nocturnal urination, hypoglycemia-like feelings, and concern about long-term dependency or unknowns. Some questioned if the benefits truly outweighed these significant downsides.
Metabolic Marvels or Mere Mass-Loss?
A central debate revolved around whether the observed benefits, including potential dementia risk reduction, were solely due to weight loss induced by semaglutide or if the drug had direct physiological effects. While the study attempted to adjust for BMI changes, commenters still questioned the extent of direct action. Some anecdotal evidence suggested health improvements (e.g., lab results, reduced inflammation, improved mobility) even before significant weight loss, pointing to mechanisms beyond just a smaller waistline, potentially related to insulin sensitivity or systemic inflammation.
Dietary Dilemmas and Public Health Debates
The conversation expanded to the broader context of modern diets and public health. Commenters discussed the impact of high-sugar, processed foods and sedentary lifestyles on diseases like diabetes and dementia, with some labeling dementia as "type-3 diabetes." There was debate over whether "big pharma" ignores diet, or if the medical establishment has been "screaming" about it for decades, with patients simply not complying. The role of food industry lobbying and the affordability/convenience of unhealthy food were also points of contention, leading to calls for stricter regulation akin to tobacco.
Research Rets & Risky Regimens
A distinct sub-discussion focused on "research-use" peptides like retatrutide, which are not FDA-approved but are being explored for conditions like T2D. While some advocated for their potential efficacy, a strong counter-argument emphasized the significant dangers of self-administering unregulated substances due to lack of testing, purity concerns, and zero recourse in case of adverse effects. The ethical implications of encouraging such use were also highlighted.